KMCRIC

A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years.

Wickens K, Black P, Stanley TV, Mitchell E, Barthow C, Fitzharris P, Purdie G, Crane J.

Clin Exp Allergy.

2012

42(7)

1071-9. 

10.1111/j.1365-2222.2012.03975.x.

22702506

http://www.ncbi.nlm.nih.gov/pubmed/22702506

Adult
Australia
Breast Feeding
Child, Preschool
Dietary Supplements*
Double-Blind Method
Eczema/epidemiology
Eczema/prevention & control*
Female
Humans
Infant
Infant, Newborn
Lactobacillus rhamnosus*
Male
Pregnancy
Pregnancy Trimester, Third
Prevalence
Probiotics/administration & dosage*
Probiotics/adverse effects
Time Factors

allergy prevention; atopic sensitization; Bifidobacterium animalis subsp lactis HN019; eczema; Lactobacillus rhamnosus HN001; paediatrics; probiotics; randomizedcontrolled trial; rhinitis

알레르기 예방; 아토피 감작; 비피도박테리움 락티스; 습진; 락토바실러스 람노서스; 소아과; 프로바이오틱스; 무작위 대조 연구; 비염

없음

BACKGROUND:
Using a double blind randomized placebo-controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 × 10(9) cfu/day) halved the cumulative prevalence of eczema by age 2 years. Bifidobacterium animalis subsp lactis HN019 (HN019) (9 × 10(9) cfu/day) had no effect.
OBJECTIVE:
The aim of this study was to investigate the associations of HN001 and HN019 with allergic disease and atopic sensitization among these children at age 4 years, 2 years after stopping probiotic supplementation.
METHODS:
The presence (UK Working Party's Diagnostic Criteria) and severity SCORing Atopic Dermatitis (SCORAD) of eczema and atopy (skin prick tests) and parent-reported symptoms of asthma and rhinoconjunctivitis were assessed using standard protocols and questions.
RESULTS:
Four-hundred and seventy-four infants were eligible at birth of whom 425 (90%) participated in this follow-up. The cumulative prevalence of eczema by 4 years (Hazard ratio (HR) 0.57 (95% CI 0.39-0.83)) and prevalence of rhinoconjunctivitis at 4 years (Relative risk 0.38 (95% CI 0.18-0.83)) were significantly reduced in the children taking HN001; there were also nonsignificant reductions in the cumulative prevalence of SCORAD ≥ 10 (HR 0.74 (95% CI 0.52-1.05), wheeze (HR 0.79 (95% CI 0.59-1.07)) and atopic sensitization (HR = 0.72 (95% CI 0.48-1.06)). HN019 did not affect the prevalence of any outcome.
CONCLUSIONS AND CLINICAL RELEVANCE:
This study showed that the protective effect of HN001 against eczema, when given for the first 2 years of life only, extended to at least 4 years of age. This, together with our findings for a protective effect against rhinoconjunctivitis, suggests that this probiotic might be an appropriate preventative intervention for high risk infants.

영어